Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenQuadfi Revaccination in Older Adults
NCT04142242Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2019
- Primary completion
- Apr 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, open-label trial of meningococcal A conjugate vaccine in meningococcal infection (6 arms), sponsored by Sanofi. Primary endpoint: Percentage of Participants With Seroresponse for Meningococcal Serogroups A, C, W & Y Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30. Started Oct 2019; status: completed.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT04142242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142242.